Join IQVIA at ISPOR Europe 2022

Real world evidence. Real confidence. Real results.

IQVIA's real world evidence experts will be contributing to a range of events at ISPOR Europe 2022 from **6–9 November** in Vienna. Join us to discover new insights from our live and on-demand panel contributions, and more than 100 posters featuring our research.

Issue panel

140 • How Shall We Analyze Change from Baseline in COA Endpoints? Is MMRM Bowing Out?

Moderator: *Ashley Slagle, PhD, MS, Aspen Consulting, USA*
Panelists: *James Bell, PhD, Elderbrook Solutions, UK; Andrew Potter, PhD, FDA-CDER, USA; Konstantina Skaltsa, PhD, IQVIA, Spain*

- Monday, 7 November • 16:30–17:30 • *Virtual*

Workshops

202 • Use of Real-World Evidence to Support Health Technology Assessment in United States, Europe and Japan

Discussion leader: *Jasmanda H Wu, PhD, MPH, FISPE, Insmed, USA*
Speakers: *Massoud Toussi, MD, PhD, MBA, IQVIA, France; Shirley Wang, PhD, MSc, Brigham and Women's Hospital, Harvard Medical School, USA; Eric Yu, MPharm, MSc, LLM, IQVIA Solutions Japan K.K; Minato-ku, Tokyo, Japan*

- Tuesday, 8 November • 10:15–11:15 • *Virtual*

312 • Sharing-of-Information in Evidence Synthesis to Strengthen HTA Decisions

Discussion leader: *Marta Soares, MSc, PhD, University of York, UK*
Discussants: *Sylwia Bujkiewicz, PhD, MSc, University of Leicester, UK; Georgios Nikolaidis, PhD, IQVIA, London, UK; Hugo Pedder, MSc, BSc, University of Bristol, UK*

- Wednesday, 9 November • 10:00–11:00 • *In-person*

Case study

HTA Acceptance of RWE in Healthcare Decision Making: A Critical Review from Seven Countries

Coppo C, Rey L, Carelli A, Díez V, Lee SM, Oliveira L, Patel A, Porrello N, Ramos T, Schach S, Schirghuber E, Sicari E, Simpson A, Le Lay Le Lay K, Thokagevistk K

- Monday, 7 November • 13:30–13:50 • *In-person*



Podium presentations

P9 • Willingness to Trade Off Life Years or Accept Risk of Dying in Time Trade-Off and Standard Gamble Exercises to Restore the Life of a Non-Healthy Family Member: Considerations for Measurement of Non-Patient Utilities

Marieke Krol, Sabina Voronetska, Laurie Batchelder

- Monday, 7 November • 11:00–11:15 • *In-person*

P17 • Can You Design and Conduct a Real-World Evidence Study That Is Transferable Between HTA Bodies?

Spyros Kolovos, Jennifer Gaultney, Sandy Leproust, Ines Guerra

- Monday, 7 November • 14:15–14:30 • *Virtual*

P60 • Use Cases for Artificial Intelligence and Machine Learning Methods to Support Health Technology Assessment

Ashley Pitcher, Tom Halmos, Lauren Poole, Catrina Richards, Raja Shankar, Yuvraj Sharma, Ines Guerra

- Wednesday, 9 November • 10:15–10:30 • *In-person*

Visit our ISPOR Europe 2022 page to discover our thought leading research and presentations
Scan or click the QR code

Posters

GENERATING THE RIGHT EVIDENCE

Explore the application of our rigorous, innovative approaches integrating unparalleled data assets and best-in-class technology-enabled analytics to deliver representative, relevant results across a range of topics and therapy areas.

IN-PERSON AND VIRTUAL POSTER SESSION 1 • MONDAY, 7 NOVEMBER • 10:00–13:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 11:15–12:15

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	CO9	IMPACT OF PATIENT BLOOD MANAGEMENT (PBM) ON THE REDUCTION OF TRANSFUSION REQUIREMENTS AND LENGTH OF HOSPITAL STAY IN PATIENTS UNDERGOING MAJOR PLANNED ORTHOPEDIC IN GERMANY **SURGERY**	Schlegel E, Henrich M, Gückler J, Ramirez de Arellano Serna A, Sanchez E, Margalef P, Roset M, Morin N
	CO30	THERAPEUTIC ROLE OF MELATONIN IN PEDIATRIC MIGRAINE: A SYSTEMATIC REVIEW AND META-ANALYSIS **NEUROLOGICAL DISORDERS**	J JL, Ak L, Dovari A, Chidirala S, Thode R, Dasari A, Venkata Sharmila U, Hyderboini R, Belekar V, Aggarwal A, Kamra S, Goyal R
	CO32	A SYSTEMATIC REVIEW OF EFFICACY AND SAFETY OF MITAPIVAT TO TREAT HEMOLYTIC ANEMIA IN PYRUVATE KINASE DEFICIENCY **SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN**	Veeranki P, Rayapureddy G, Kummari P, Mir J, Manne M, Chidirala S, Hyderboini R, Rajput A, Kohli IS, Goyal R, Aggarwal A, Tanushree C
	CO37	REDUCTION OF LENGTH OF HOSPITAL STAY IN PATIENTS UNDERGOING MAJOR PLANNED ORTHOPEDIC SURGERY AFTER THE IMPLEMENTATION OF THE PATIENT BLOOD MANAGEMENT (PBM) IN ITALY **SURGERY**	Scardino M, Tanzi D, Morin N, Roset M, Zonta E, Lara N, Ramirez de Arellano Serna A
ECONOMIC EVALUATION	EE45	BUDGET IMPACT ANALYSIS OF INTRODUCING AMINO ACID FORMULA TO INFANTS WITH COW'S MILK PROTEIN ALLERGY IN EGYPT **PEDIATRICS, NUTRITION**	Samey G, Yousef S, ELHodHod M, Elmashad A, Emile A, M. El-Asheer O, Ezz El Regal Abbas M, Fouad A, Gamal Y, M.Barakt T, Sharma J, El Ojeil R
	EE51	EPIDEMIOLOGIC AND ECONOMIC ANALYSIS OF EARLY ANTIRETROVIRAL THERAPY WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN KINGDOM OF SAUDI ARABIA **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Mestouri A, Sarhiri J, Zimovetz E, Bakry M, Wali G
	EE95	ECONOMIC BURDEN OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA IN COLOMBIA **DIABETES/ENDOCRINE/METABOLIC DISORDERS (INCLUDING OBESITY), GERIATRICS, DRUGS**	Robles A, Gil Rojas Y, Amaya D, Sardi Correa C, Hernández F
	EE102	ECONOMIC AND ORGANISATIONAL IMPACT OF AN INNOVATIVE TREATMENT WITH EXTENDED DURABILITY FOR RETINAL DISEASES REDUCING THE ANNUAL FREQUENCY OF INTRAVITREAL INJECTIONS IN FRANCE **DRUGS**	Bourel G, Monnier R, Ba S, Guillet JP, Havet D, Pibre S, Laloux M, Le Lay K, Roula A
	EE103	EVALUATING THE NEED FOR AUTOMATED TECHNOLOGY SOLUTIONS IN ANNUAL THERAPY COST CALCULATIONS IN GERMAN EARLY BENEFIT ASSESSMENT DOSSIERS **ONCOLOGY**	Gossmann JA, Drews J, Schnauffer D, Rauch M, Kullnigg A, Meier C, Otto J
	EE119	COMBINING WILLINGNESS TO PAY VALUES FROM A DISCRETE-CHOICE EXPERIMENT WITH THE QALY FRAMEWORK IN AN ECONOMIC EVALUATION OF A PUBLIC HEALTH INTERVENTION **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Botha W, Yurdakul S
EPIDEMIOLOGY & PUBLIC HEALTH	EPH14	PREVALENCE OF DEPRESSION IN JAPAN AND THE US POPULATIONS BEFORE AND DURING THE COVID-19 PANDEMIC: A RETROSPECTIVE OBSERVATIONAL STUDY USING REAL-WORLD DATA **MENTAL HEALTH (INCLUDING ADDITION), DRUGS**	Demiya S, Takeno S, Kim SW, Lee WS, Sakai Y
	EPH38	FAMILIAL HYPERCHOLESTEROLEMIA AND RISK OF CARDIOVASCULAR DISEASE: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES **CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY)**	Mir J, Akhter Y, Manne M, Tanushree C, Kummari P, Gurram NS, Vagicharla RB, Pulleddula K, Sharma S, Chidirala S, Veeranki P, Goyal R, Aggarwal A

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 1 • MONDAY, 7 NOVEMBER • 10:00–13:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 11:15–12:15

TOPIC	CODE	TITLE	AUTHORS
HEALTH POLICY & REGULATORY	HPR27	IS IT POSSIBLE TO ANTICIPATE THE RISK OF MAJOR RESERVATION ISSUED BY THE CEESP? A RETROSPECTIVE ANALYSIS OF PUBLISHED OPINIONS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Duteil E, Rey L, Monnier R, Bizouard G, Leproust S
	HPR34	EMERGING ROLE OF PATIENT REPORTED OUTCOMES IN DRUG APPROVAL IN EUROPE **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Pal S, Magimaidas RV, Sreedharan S, Ghosh S, Chatterjee M
	HPR36	EVALUATING PATIENT PREFERENCE INFORMATION IN REGULATORY DECISION-MAKING **DRUGS**	Batchelder L, Pérez López NG, Darpelly M, Whitsett J
HEALTH SERVICE DELIVERY & PROCESS OF CARE	HSD20	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AFTER INTRODUCTION OF IMMUNE CHECKPOINT INHIBITORS (ICIS) IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (ANSCLC) IN EUROPE (EU4+UK) **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Slowley A, Kalilani L, Multani J, Casey V, Mpima S, Yasuda M, Chen CC, Manuguid F, Chao J, Aziez A, Bell K, Stojadinovic A
HEALTH TECHNOLOGY ASSESSMENT	HTA22	ITC APPRAISAL BY FRENCH HTA COMMITTEES: COMPREHENSIVE REVIEW AND COMPARISON **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Monnier R, Rey L, Baschet L, Kaboré N, Perrin L, Leproust S
	HTA24	REAL-WORLD DATA AS EXTERNAL CONTROLS FOR SINGLE-ARM TRIALS: ROLE IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENTS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Tomeczkowski J, Partemio G, Nijhuis T, Kubitz N, Kavanagh S
	HTA27	IMPLICATIONS OF AN EU-WIDE JOINT CLINICAL ASSESSMENT ON THE SCOPE OF THE DECISION PROBLEM **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Almeida J, Gaultney J
	HTA32	DOES A MAJOR ADDED BENEFIT FROM THE G-BA CORRESPOND TO POSITIVE OUTCOMES ACROSS MAJOR MARKETS? AN ANALYSIS BASED ON THE PRISMACCESS DATABASE **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Kasli I, El Saleh S
	HTA38	WHEN AND HOW DOES RWE IMPACT HTA OUTCOMES IN ONCOLOGY? A QUALITATIVE EVALUATION OF CASE STUDIES TO IDENTIFY DRIVERS OF RWE ACCEPTANCE TODAY AND IN THE FUTURE **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Oswald C, Anastasaki E, Dunton K, van Engen A, Liljas B, Mbanya Z, Parry D, Rosenlund M, Szawara P
MEDICAL TECHNOLOGIES	MT6	REAL WORLD CLINICAL DATA ON THE USE OF A NATURAL MOLECULAR COMPLEX FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME IN SPECIALIST DAILY PRACTICE **MEDICAL DEVICES**	Cioeta R, Cipelli R, Panzieri F, Urbinati D, Idone V, Cossu A
METHODOLOGICAL & STATISTICAL RESEARCH	MSR13	METHODS FOR HANDLING EQ-5D MISSING VALUES IN COST-EFFECTIVENESS ANALYSES (CEA) AND PATIENT-REPORTED OUTCOME (PRO) STUDIES: A TARGETED LITERATURE REVIEW **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Li Y, Soulanis K, Guerra I
	MSR19	AN UPDATE ON REAL-TIME APPLICATION OF MACHINE LEARNING PROGRAMS TO IMPROVE CARDIOVASCULAR RISK PREDICTION IN EUROPEAN POPULATION **CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY)**	Trikha S, Mothay D, Ghosh S, Mahajan K, Chatterjee M, Aggarwal A
PATIENT-CENTERED RESEARCH	PCR8	EXPLORING PREFERENCES OF DIFFERENT MODES OF ADMINISTRATION OF HYPOMETHYLATING (HMA) TREATMENTS AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Eberhardt A, Delmas A, Batchelder L, Arora I, Bayet S, Philpott S, Rodriguez-Leboeuf AM, Bruhn D
	PCR14	A LITERATURE REVIEW OF METHODOLOGY USED IN IN-TRIAL INTERVIEW STUDIES IN CLINICAL DEVELOPMENT **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Alladin A, Barrio J, Dikariyanto V, Venerus M, Rolst M, Krol M
	PCR37	UNDERSTANDING SYMPTOMS AND MEANINGFUL CHANGE IN PATIENT GLOBAL IMPRESSION SCALES FOR PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (ADV/MET NSCLC): A QUALITATIVE RESEARCH STUDY **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Kelly K, Cardellino A, Shah M, Hanlon J, Taiyari S, Roborel de Climens A, Stojadinovic A
	PCR48	MEANINGFUL CHANGE IS A PERCEPTION, NOT ONLY A NUMBER: A REVIEW OF QUALITATIVE INTERVIEWS EXPLORING MEANINGFUL CHANGES IN SYMPTOMS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Philpott S, Macdonald E, Krupnick RN

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 1 • MONDAY, 7 NOVEMBER • 10:00–13:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 11:15–12:15

TOPIC	CODE	TITLE	AUTHORS
REAL-WORLD DATA & INFORMATION SYSTEMS	RWD13	REAL WORLD CRITERIA USED TO DIAGNOSE RELAPSED/REFRACTORY STATUS OF PATIENTS WITH MULTIPLE MYELOMA IN GERMANY **RARE AND ORPHAN DISEASES**	Flossmann C, Ertel F, Piesch S, Thun B, Stolpe T
	RWD22	NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE (NTM-PD) MANAGEMENT IN BELGIUM: A LONGITUDINAL PHARMACY DATABASE STUDY **INFECTIOUS DISEASE (NON-VACCINE), RARE & ORPHAN DISEASES, RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY)**	Peeters E, van der Laan R, Chevalier P, Cai R, Obradovic M, Lorent N
STUDY APPROACHES	SA9	RWE PATHWAY: THE STATE-OF-THE-ART OF PATIENT REGISTRIES IN PORTUGAL **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Pedrosa H, Pereira F, Carrilho M, Martins C, Martins R, Cruz P

IN-PERSON AND VIRTUAL POSTER SESSION 2 • MONDAY, 7 NOVEMBER • 15:00–18:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 15:00–16:00

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	CO50	EFFICACY AND SAFETY OF ITOLIZUMAB FOR THE TREATMENT OF CORONAVIRUS DISEASE (COVID-19): A SYSTEMATIC LITERATURE REVIEW **RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY)**	Gurram NS, Vagicharla RB, Rayapureddy G, Kummari P, Pulleddula K, Mir J, Sharma S, Tanushree C, Kohli IS, Goyal R, Aggarwal A, Chakrawarthy M
	CO51	EFFICACY AND SAFETY OF VONOPRAZAN TRIPLE THERAPY (VONOPRAZAN, AMOXICILLIN, CLARITHROMYCIN) IN PATIENTS WITH HELICOBACTER PYLORI INFECTION: SYSTEMATIC REVIEW & META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS **GASTROINTESTINAL DISORDERS, INFECTIOUS DISEASE (NON-VACCINE)**	J JL, Ak L, Dovari A, Thode R, Chidirala S, Juturuvenkata K, Dasari A, Hyderboini R6, Belekar V7, Kamra S, Aggarwal A, Goyal R
STUDY APPROACHES	EE166	COST-EFFECTIVENESS OF THE PNEUMOCOCCAL CONJUGATE VACCINE 10 VERSUS 13 ON PNEUMOCOCCAL DISEASE IN CHILDREN IN SWEDEN **PEDIATRICS, RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY)**	Peeters E, Marijam A, Chevalier P, Ene J, Folkesson J, Izurieta P, Joost S, Urbonas G, Adbelghany M
	EE227	HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH USTEKINUMAB: REAL-WORLD EVIDENCE **GASTROINTESTINAL DISORDERS, BIOLOGICS & BIOSIMILARS**	Bessissow T, Narula N, Ma C, In TSH, Eberg M, Pone E, Jairath V
	E237	REIMBURSABLE DIGITAL HEALTHCARE APPLICATIONS (DIGAS) IN GERMANY: PRICE DEVELOPMENTS AND PAYER PERSPECTIVE **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Drews J, Maier M, Schuller JM, Dose J, Böckmann D, Ernst I, Ismagambetova A, Bonduelle D
	EE269	EVOLUTION AND IMPLICATIONS OF THE PORTUGUESE HTA FRAMEWORK ON HEALTH ECONOMICS IN PATIENTS' ACCESS TO INNOVATION **RARE & ORPHAN DISEASES, DRUGS, PERSONALIZED & PRECISION MEDICINE**	Silva Miguel L, Maia-Lopes S, Ferreira LN, Castro Alves E, Gaultney J, Gonçalves P, Rotaru M, Beja da Costa L, Pedrosa H, André S
	EE270	ECONOMIC BURDEN OF YOUNG ONSET PARKINSON'S DISEASE: A SYSTEMATIC LITERATURE REVIEW **NEUROLOGICAL DISORDERS**	Pulleddula K, Rayapureddy G, Gurram NS, Kummari P, Vagicharla RB, Mir J, Tanushree C, Sharma S, Kohli IS, Goyal R, Aggarwal A, Chakrawarthy M
EPIDEMIOLOGY & PUBLIC HEALTH	EPH61	OBESITY AND GLYCEMIC CONTROL AMONG PEOPLE WITH TYPE 2 DIABETES IN EUROPE: A RETROSPECTIVE COHORT ANALYSIS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Newson RS, Divino V, Vallarino C, Chen J, DeKoven M, Ranta K, Boye KS
	EPH82	PHARMACOTHERAPY OF OBESITY IN THE RUSSIAN FEDERATION: PHARMACOEPIDEMIOLOGICAL STUDY **DIABETES/ENDOCRINE/METABOLIC DISORDERS (INCLUDING OBESITY), DRUGS**	Kolbin A, Gomon J, Spichakova E, Kalyapin A, Lomiya A, Balykina Y

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 2 • MONDAY, 7 NOVEMBER • 15:00–18:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 15:00–16:00

TOPIC	CODE	TITLE	AUTHORS
HEALTH POLICY & REGULATORY	HPR59	THE PHARMACEUTICAL REIMBURSEMENT AND ACCESS PATHWAYS IN THE 27 EU MEMBER STATES: WHO IS READY FOR JOINT EU HTA? **ONCOLOGY, DRUGS, GENETIC, REGENERATIVE & CURATIVE THERAPIES**	Kruger R, van Engen A, Wagner P, Aggarwal A, Spinas N
	HPR72	REGIONAL HETEROGENEITY OF THE DESIGN AND OUTCOMES OF DRUG TENDERING IN ITALY **BIOLOGICS & BIOSIMILARS, GENERICS**	Mastrorilli G, Tucci C, Fiorentino F, Tettamanti A, Brocca A, Zoia C, Barbato D, Faraone V, Martocchia Diodati N, Mossa S, Urbinati D
	HPR77	VARIABLES IMPACTING DRUGS AVERAGE PRICES IN ITALY IN 2016–2021 PERIOD **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Rova A, Canali B, Candelora L, Fiorentino F, La Malfa P, Mattu I, Urbinati D
HEALTH TECHNOLOGY ASSESSMENT	HTA61	CHALLENGES IN SELECTING RELEVANT COMPARATOR THERAPIES IN INDICATIONS WITH LOW EVIDENCE USING THE EXAMPLE OF GERMAN BENEFIT ASSESSMENTS WITH THE APPROPRIATE COMPARATOR THERAPY "TREATMENT OF PHYSICIANS CHOICE" **DRUGS**	Mattern F, Bruns C, Kovacevic S, Eheberg D
	HTA63	IMPLEMENTATION AND APPLICATION OF THE PHYSICIAN INFORMATION SYSTEM (ARZTINFORMATIONSSYSTEM, AIS) IN GERMANY **DRUGS**	Mattern F, Schnauffer D, Wiest T, Cook J, Gallinger P
	HTA71	WILL THE NEW EU HTA REGULATIONS INCREASE THE METHODOLOGICAL REQUIREMENTS TO CONDUCTING SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EVIDENCE? **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Rtveladze K, Kamra S, Gogna S, Gaultney J
	HTA77	THE USE AND ACCEPTABILITY OF EXTERNAL COMPARATOR STUDIES TO SUPPORT HEMATO-ONCOLOGY SINGLE-ARM TRIAL SUBMISSIONS TO HEALTH TECHNOLOGY ASSESSMENT BODIES **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Dijkhuis S, Patel D, Foster S, van Engen A, van Gils C
	HTA85	POSSIBLE IMPACT OF ORPHAN THRESHOLD REDUCTION TO 20 MILLION EURO IN THE FRAMEWORK OF EARLY BENEFIT ASSESSMENT AND REIMBURSEMENT PRICE IN GERMANY **RARE & ORPHAN DISEASES**	Batscheider A, Shlaen E, Rich A, Meier C, Weiß K, Kovacevic S, Greiner RA
	HTA87	EVALUATING THE FRAMEWORK AND EVOLUTION OF THE ITALIAN MINISTRY OF HEALTH HTA REPORTS **DRUGS**	Mantuano M, La Malfa P, Freddi R, Urbinati D, Lombardi G
	HTA88	SIMILARITIES AND DIFFERENCES IN SCIENTIFIC ADVICE PROCESSES **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Gallinger P, Bonduelle D, Gaultney J, Streicher S, van Engen A
	HTA96	HEALTH ECONOMIC MODELLING FOR HTA ASSESSMENT: A COMPARISON OF ECONOMIC PROTOCOLS SUBMITTED TO THREE HTA BODIES (HAS, NICE, CADTH) **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Poignant P, Chambry L, Duteil E, Leproust S
	HTA97	IMPACT OF ADDITIVE PICOS IN A EUROPEAN JOINT HEALTH TECHNOLOGY ASSESSMENT. A HYPOTHETICAL CASE STUDY IN LUNG CANCER **DRUGS**	van Engen A, Kruger R, Ryan J, Wagner P
METHDOLOGICAL & STATISTICAL RESEARCH	MSR42	ADOPTION OF ARTIFICIAL INTELLIGENCE IN SYSTEMATIC REVIEWS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Bhagat A, Moon D, Khan H, Kochar P, Kanakagiri S, Kaur R, Bhalla Y, Kaur K, Singh R, Goyal R, Aggarwal A
PATIENT-CENTERED RESEARCH	PCR80	HEALTH-RELATED QUALITY OF LIFE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB IN RANDOMIZED CONTROLLED TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS **GASTROINTESTINAL DISORDERS**	Geddamuri BG, Thode R, Dasari A, Hyderboini R, Chidirala S, Nadimpally J, Kamra S, Goyal R, Aggarwal A

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 2 • MONDAY, 7 NOVEMBER • 15:00–18:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 15:00–16:00

TOPIC	CODE	TITLE	AUTHORS
REAL-WORLD DATA & INFORMATION SYSTEMS	RWD52	RELEVANT REAL-WORLD EVIDENCE LANDSCAPING AND DATA SOURCE ASSESSMENT FOR VITILIGO PATIENT RESEARCH IN EUROPE **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Delattre C, Bolic J, Girardat-Rotar L, Amara Korba A, Flostrand S, Patel D
	RWD55	IMMUNOSUPPRESSIVE (IS) TREATMENT PATTERNS FOLLOWING KIDNEY TRANSPLANT IN FRANCE: A REAL-WORLD RETROSPECTIVE COHORT USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS) CLAIM DATABASES OISTER STUDY **SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN)**	Anglicheau D, Durrbach A, Bardoulat I, Arnaud M, Fouad F, Cotte FE, Vadanici R, Chartier M, Glotz D
	RWD56	MACHINE LEARNING FOR CLUSTERING DYSLIPIDEMIA PATIENTS WITH STATIN INTOLERANCE IN GERMANY **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Rathore A, Anastassopoulou A, Parhofer KG, Becker C, Zamfir C, Calver H, Dave R
STUDY APPROACHES	SA33	DEMOGRAPHIC CHARACTERISTICS OF PATIENTS INITIATING TOPICAL COMBINATION THERAPIES FOR PLAQUE PSORIASIS IN CANADA: A CLAIMS-BASED ANALYSIS **DRUGS**	Gaudet V, Yang H, Bourgoin T, Sharma A, Barbeau M

IN-PERSON AND VIRTUAL POSTER SESSION 3 • TUESDAY, 8 NOVEMBER • 10.00–13:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 11:15–12:15

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	CO83	REDUCTION OF TRANSFUSION REQUIREMENTS AND LENGTH OF HOSPITAL STAY IN PATIENTS UNDERGOING MAJOR PLANNED SURGERY AFTER THE IMPLEMENTATION OF PATIENT BLOOD MANAGEMENT (PBM) IN SPAIN **SURGERY**	Colomina MJ, De La Fuente Graciani I, Pereda-Manso A, Barquero M, Mendez E, Morin N, Lara N, Illa C, Ramirez de Arellano Serna A, Roset M, Ruiz N
ECONOMIC EVALUATION	EE300	HEALTH CARE RESOURCE UTILISATION (HCRU) AND CORRESPONDING COSTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) ADMISSIONS BEFORE THE AGE OF TWO IN ENGLAND **INFECTIOUS DISEASE (NON-VACCINE), RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY)**	Davidson C, Fonseca MJ, Bangert M, Cirneanu L, Hudson R
	EE341	ECONOMIC EVALUATIONS OF TECHNOLOGIES FOR THE TREATMENT OF RARE DISEASES IN LATIN AMERICA AND SOUTHEAST ASIA: A SCOPING REVIEW **MUSCULOSKELETAL DISORDERS (ARTHRITIS, BONE DISORDERS, OSTEOPOROSIS, OTHER MUSCULOSKELETAL), NEUROLOGICAL DISORDERS, RARE & ORPHAN DISEASES**	Gil-Vaca EN, Valderrama-Rios MC, Vargas-Peláez CM, Hernández F
	EE353	RESOURCE UTILISATION AND HEALTHCARE COSTS AMONG PATIENTS WITH MAJOR DEPRESSION AND ACTIVE SUICIDAL IDEATION WITH INTENT IN ITALY: INITIAL FINDINGS FROM THE ARIANNA OBSERVATIONAL SUBSTUDY **NEUROLOGICAL DISORDERS**	Sansone C, Adami M, Cipelli R, Franchi A, Maffezzoli S, Roncari B, Delmonte D
	EE379	POTENTIAL HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS OF EVERY 2-MONTHS INJECTABLE CABOTEGRAVIR+RILPIVIRINE LONG-ACTING IMPLEMENTATION IN THE SPANISH NHS VS DAILY ORAL HIV TREATMENTS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Vallejo-Aparicio LA, Neches V, Hernández Novoa B, Casado G, Jodar F, Pinel M, Callejo-Velasco D
	EE384	A TARGETED LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES IN NEUROMYELITIS OPTICA SPECTRUM DISORDER **NEUROLOGICAL DISORDERS, RARE & ORPHAN DISEASES**	Aggarwal A, Dasari A, Belekar V, Dovari A, Ravi Kishore H, Chidirala S, Goyal R, Singh R, Kataria AK
EPIDEMIOLOGY & PUBLIC HEALTH	EPH108	HOSPITAL ECONOMIC BURDEN OF HEART FAILURE (HF) IN FRANCE **CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY), DIABETES/ENDOCRINE/METABOLIC DISORDERS (INCLUDING OBESITY)**	Chemouni F, Groyer H, Nishikawa TC, Diaby O, Chollet J, Ittah D

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 3 • TUESDAY, 8 NOVEMBER • 10:00–13:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 11:15–12:15

TOPIC	CODE	TITLE	AUTHORS
HEALTH POLICY & REGULATORY	HPR97	NATIONAL REIMBURSEMENT DRUG LIST NEGOTIATION IN CHINA: ANALYSIS OF THE KEY TRENDS AND FACTORS INFLUENCING THE VALUE APPRAISAL AND PRICE DETERMINATION **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Xie Y, Ming J, Zhao X, Liu J, Li HJ, Qu S, Hu S
	HPR103	PRICING NEGOTIATIONS OF ASMR IV DRUGS IN FRANCE: IMPACT OF THE LATEST LEEM-CEPS FRAMEWORK AGREEMENT **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Pouxviel N, Duckit A, Duteil E, Epis De Fleurian AA, Troubat A
	HPR108	IMPACT OF COVID-19 PANDEMIC ON THE DECISION PROCESS OF THE ITALIAN MEDICINE AGENCY: A QUANTITATIVE ASSESSMENT **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, DRUGS**	Fiorentino F, Canali B, Candelora L, Halmos T, La Malfa P, Massara F, Vassallo C, Urbinati D
	HPR120	NEGOTIATING NEW THERAPEUTIC INDICATIONS IN ITALY: WHICH IMPACT ON DRUG REIMBURSEMENT CONDITIONS AND TIMING? **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Candelora L, Canali B, Fattore C, Fiorentino F, La Malfa P, Manini B, Urbinati D
	HPR129	REIMBURSEMENT STATUS OF EUROPEAN MEDICINES AGENCY AUTHORISED DRUGS IN SPAIN **DRUGS**	Carmo M, Aguilar L, Pinel M, Perulero N, Rebollo P, Merino-Montero S, Callejo-Velasco D
HEALTH SERVICE DELIVERY & PROCESS OF CARE	HSD55	EXPANDING VACCINE COMPETENCIES TO COMMUNITY PHARMACISTS: MODELLING ORGANIZATIONAL AND ECONOMIC IMPACTS OF NEW HUMAN PAPILLOMA VIRUS (HPV) VACCINES PATHWAYS IN FRANCE **VACCINES**	Mamane C, Bongiovanni-Delaroziere I, Foerst C, Mourlat B, Farge G, Bensimon L
HEALTH TECHNOLOGY ASSESSMENT	HTA144	EVOLUTION AND IMPLICATIONS OF THE PORTUGUESE HTA FRAMEWORK ON ADDED THERAPEUTIC VALUE IN PATIENTS' ACCESS TO INNOVATION **RARE & ORPHAN DISEASES, DRUGS, PERSONALIZED & PRECISION MEDICINE**	Costa J, Maia-Lopes S, Castro Alves E, Birne R, Silva Miguel L, Rocha L, Beja da Costa L, Pedrosa H, André S
	HTA156	ANALYSIS OF THE EARLY ACCESS REFORM AND TRENDS OBSERVED IN THE EVALUATION BY THE HAS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, DRUGS**	Gontier P, Sahri W, Epis De Fleurian AA, Troubat A
MEDICAL TECHNOLOGIES	MT25	MOBILE HEALTH INTERVENTIONS IN MENTAL HEALTH CONDITIONS: A REVIEW ON DEVELOPMENT SO FAR AND GAPS TO BE BRIDGED **MENTAL HEALTH (INCLUDING ADDITION)**	Chatterjee M, Arora K, Chatterjee K
REAL-WORLD DATA & INFORMATION SYSTEMS	RWD70	ELECTRONIC IMPLEMENTATION OF PATIENT-REPORTED OUTCOMES: CHALLENGES AND POTENTIAL SOLUTIONS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Cassanelli F, Ferri F, Ori A, Simoni L
	RWD76	REAL-WORLD PATIENT PERSISTENCE AND COMPLIANCE: A COMPARISON OF PROSTAGLANDIN ANALOGS USED FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Laforty C, Feener S, Sharma A, Barbeau M
	RWD88	EXAMINING THE FITNESS-FOR-PURPOSE OF EUROPEAN REAL-WORLD DATA SOURCES FOR EXTERNAL COMPARATORS IN HAEMATOLOGICAL MALIGNANCIES **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Saunders A, Hogg C, Jeswani N, Masi D, Papsch R
	RWD100	LEVERAGING REAL WORLD DATA SOURCES TO ESTIMATE RANGES FOR DISTRIBUTIONS OF PATIENT ETHNICITY AND RACE IN U.S. CLINICAL TRIALS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Gemmen E

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 4 • TUESDAY, 8 NOVEMBER • 15:00–18:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 15:00–16:00

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	CO115	IMPACT OF PATIENT BLOOD MANAGEMENT (PBM) ON THE REDUCTION OF TRANSFUSION REQUIREMENTS IN PATIENTS UNDERGOING MAJOR PLANNED ORTHOPEDIC SURGERY IN ITALY **SURGERY**	Scardino M, Tanzi D, Ramirez de Arellano Serna A, Zonta E, Sanchez E, Lara N, Morin N
	CO138	IMPACT OF TELEMEDICINE ON THE CLINICAL, ECONOMIC, AND HUMANISTIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS, BEFORE AND DURING THE COVID-19 PANDEMIC: A TARGETED LITERATURE REVIEW **RESPIRATORY-RELATED DISORDERS (ALLERGY, ASTHMA, SMOKING, OTHER RESPIRATORY)**	Dhanal M, Barathe P, Tanushree C, Sharma S, Mir J, Kohli IS, Goyal R, Aggarwal A, Chakrawarthy M
ECONOMIC EVALUATION	EE480	COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH HEART FAILURE WITH ABOVE 40% EJECTION FRACTION IN ENGLAND **CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY)**	Kolovos S, Tasoulas A, Solé Angelats A, Linden S, Bellanca L
	EE481	COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR PATIENTS WITH HEART FAILURE IRRESPECTIVE OF EJECTION FRACTION IN ENGLAND **CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY)**	Cheen M, Gaultney J, Bellanca L, Linden S
	EE483	EMPAGLIFLOZIN FOR HEART FAILURE PATIENTS IRRESPECTIVE OF EJECTION FRACTION IN SPAIN: A COST-EFFECTIVENESS STUDY **CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY)**	Croci F, Kolovos S, Bellanca L, Linden S, Solé Angelats A
	EE516	BUDGET-IMPACT MODEL OF ADALIMUMAB-BIOSIMILAR SANDOZ IN THE MANAGEMENT OF AUTOIMMUNE DISEASES IN THE MIDDLE EAST **SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN), BIOLOGICS & BIOSIMILARS**	Alnaqbi DKA, Alsennani F, Aloqaili DL, Alowaimer DB, Merashli DM, Kurban DM, Daniel DF, Saab N, Sharma J, Zimovetz E
HEALTH POLICY & REGULATORY	HPR137	RESOURCE UTILIZATION TRENDS RELATED WITH PRECISION ONCOLOGY IN CHILE **ONCOLOGY, PERSONALIZED & PRECISION MEDICINE**	Cayun Pellizaris J, Hernández F
	HPR151	HAS PROJECT ORBIS FACILITATED FASTER ACCESS TO ONCOLOGY THERAPIES IN GREAT BRITAIN FOLLOWING 'BREXIT'? **DRUGS**	Kasli I
	HPR162	ANALYSIS OF INTRA-REGIONAL VARIABILITY OF DRUGS' TIME TO ACCESS IN ITALY **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Fattore C, Canali B, Candelora L, Fiorentino F, La Malfa P, Mazza G, Urbinati D
HEALTH TECHNOLOGY ASSESSMENT	HTA206	USE OF REAL-WORLD DATA IN SYSTEMATIC LITERATURE REVIEWS CONDUCTED FOR HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS IN EUROPE **INFECTIOUS DISEASE (NON-VACCINE), ONCOLOGY, RARE & ORPHAN DISEASES**	Dasari G, Mulkalapalli N, Bongale AA, Rajput A, Kamra S, Gaultney J
	HTA215	COMPARISON OF FRENCH HTA PARALLEL APPRAISAL PERFORMED BY THE ECONOMIC AND PUBLIC HEALTH COMMITTEE (CEESP) AND THE TRANSPARENCY COMMITTEE (TC) FOR A SAME PRODUCT: ARE THE CONCLUSIONS OF THE TWO COMMITTEES CONSISTENT? **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Monnier R, Chambry L, Leproust S, Duteil E
METHODOLOGICAL & STATISTICAL RESEARCH	MSR98	INCORPORATING COVARIATES IN HEALTHCARE DECISION-MAKING: EMPIRICAL APPLICATION OF METHODS IN A COST-EFFECTIVENESS MODEL FOR IVIG IN SEVERE SEPSIS **INJURY & TRAUMA, SYSTEMIC DISORDERS/CONDITIONS (ANESTHESIA, AUTO-IMMUNE DISORDERS (N.E.C.), HEMATOLOGICAL DISORDERS (NON-ONCOLOGIC), PAIN)**	Mantopoulos T, Dias S, Welton N, Soares M
	MSR100	APPLICABILITY OF ARTIFICIAL INTELLIGENCE IN TARGETED LITERATURE REVIEW **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Rajadhyax A, Moon D, Bhagat A, Khan H, Sharma S, Gupta P, Sharma S, Randhawa S, Singh I, Singh R, Goyal R, Aggarwal A

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 4 • TUESDAY, 8 NOVEMBER • 15:00–18:15

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 15:00–16:00

TOPIC	CODE	TITLE	AUTHORS
PATIENT-CENTERED RESEARCH	PCR185	THE ROLE OF PATIENTS' ADVOCACY GROUPS IN THE ITALIAN HEALTH CARE ECOSYSTEM: PRESENT AND FUTURE PERSPECTIVES **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Vezzola PM, Caputo N, Cazzaniga S, Urbinati D, Fiorentino F, Cecchini IML
	PCR199	TIME TO FIRST DETERIORATION IN HEALTH-RELATED QUALITY OF LIFE (HRQOL) REMAINS THE MOST COMMON TIME TO DETERIORATION (TTD) IN NON-SMALL LUNG CANCER (NSCLC) TRIALS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Tasouli F, Casamayor M, Ivanescu C
	PCR212	SYMPTOMS AND IMPACTS IMPORTANT TO PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (ADV/MET NSCLC): RESULTS OF A QUALITATIVE RESEARCH STUDY **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Cardellino A, Shah M, Hanlon J, Taiyari S, Kelly K, Roborel de Climens A, Stojadinovic A
	PCR216	SOCIAL DISCONNECTEDNESS IS A MENTAL HEALTH CONCERN FOR YOUNG ADOLESCENTS **MENTAL HEALTH (INCLUDING ADDITION)**	Jagannathan Tearle S, Ram Guguloth R, Anjum Chintakunta M, Masood R, Harinarayan P, Jagannathan S
	PCR225	QUALITY OF LIFE (QOL)-RELATED MENTIONS FOR PREVALENT DISEASES ON SOCIAL MEDIA PLATFORMS IN THE US **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Onwude O, Casamayor M, Saraykar T, Shome R, Reaney M
REAL-WORLD DATA & INFORMATION SYSTEMS	RWD114	INVESTIGATING THE IMPACTS OF COMORBID CONDITIONS ON COSTS AND LENGTH OF STAY IN SECONDARY CARE AMONG ADULTS INFECTED WITH INFLUENZA IN ENGLAND **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	de Courville C, Bricout H, Alvarez FP, Clouting J, Patel S, Mohamed H, Coles B

IN-PERSON AND VIRTUAL POSTER SESSION 5 • WEDNESDAY, 9 NOVEMBER • 09:00–12:30

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 09:00–10:00

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	CO158	SURVEY ON THE REAL-WORLD EFFECTIVENESS AND USAGE OF VENETOCLAX AND RELATED HEALTH CARE RESOURCE UTILIZATION IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY **ONCOLOGY**	Zhao X, Mo X, Zhao J, Liu J
	CO170	EFFICACY AND SAFETY OF GOLIMUMAB IN PEDIATRIC ULCERATIVE COLITIS: A SYSTEMATIC LITERATURE REVIEW **GASTROINTESTINAL DISORDERS**	Kummari P, Gurram NS, Rayapureddy G, Pulleddula K, Chidirala S, Veeranki P, Mir J, Vagicharla RB, Manne M, Rajput A, Goyal R, Aggarwal A, Tanushree C
	CO173	EFFICACY AND SAFETY OF DARIDOREXANT IN PATIENTS WITH INSOMNIA: SYSTEMATIC REVIEW & META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS **MENTAL HEALTH (INCLUDING ADDITION)**	Chidirala S, Rayapureddy G, Dasari A, Kummari P, Veeranki P, Manne M, Mir J, Hyderboini R, Kohli IS, Goyal R, Aggarwal A, Tanushree C
ECONOMIC EVALUATION	EE578	A TWO-PRONGED APPROACH TO MANAGE ECONOMIC BURDEN OF DISEASE AND THERAPY: A PERSPECTIVE FOR ALZHEIMER'S DISEASE **GERIATRICS**	Puli LK, Maddirela D, Kumar S, Narang A, Taneja L, Chatterjee M
	EE633	A TARGETED LITERATURE REVIEW OF THE MODELLING APPROACHES AND CHALLENGES IN EARLY-STAGE ONCOLOGY TREATMENT SEQUENCE MODELS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Li Y, Lashilola S, Guerra I
	EE643	A TARGETED REVIEW OF COST-EFFECTIVENESS OF IMMUNOTHERAPIES USED IN TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER PATIENTS IN EU-5, SWEDEN, AND SWITZERLAND **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS, ALTERNATIVE MEDICINE, DRUGS**	Trikha S, Mehta M, Ghosh S, Chatterjee M, Mahajan K, Aggarwal A
	EE649	CONTRASTING 4 DIFFERENT MORTALITY PREDICTIONS IN PATIENTS WITH TYPE 1 DIABETES USING THE IQVIA CORE DIABETES MODEL **CARDIOVASCULAR DISORDERS (INCLUDING MI, STROKE, CIRCULATORY), DIABETES/ENDOCRINE/METABOLIC DISORDERS (INCLUDING OBESITY)**	Martins L, Ramos M, Lamotte M

Click here for details of posters available on the ISPOR Europe 2022 website

IN-PERSON AND VIRTUAL POSTER SESSION 5 • WEDNESDAY, 9 NOVEMBER • 09:00–12:30

PRESENTING AUTHORS WILL BE WITH THEIR POSTERS FROM 09:00–10:00

TOPIC	CODE	TITLE	AUTHORS
EPIDEMIOLOGY & PUBLIC HEALTH	EPH199	EPIDEMIOLOGY OF EYE DISORDERS DUE TO THE USE OF VIDEO DISPLAY TERMINALS IN FRANCE, GERMANY, ITALY, SPAIN AND UNITED KINGDOM – A SYSTEMATIC LITERATURE REVIEW **SENSORY SYSTEM DISORDERS (EAR, EYE, DENTAL, SKIN)**	Pagidigummula R, Yadav H, Kaur D, Verma A, Kataria A, Goyal R, Aggarwal A
HEALTH POLICY & REGULATORY	HPR193	INVESTIGATING THE CORRELATION BETWEEN UK-BASED CLINICAL RESEARCH AND NICE DECISION MAKING **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Banks C, Taylor H, Halmos T, Poole L, Ohlmeyer V, Hogan N, Shankar R
HEALTH TECHNOLOGY ASSESSMENT	HTA250	HEALTH TECHNOLOGY ASSESSMENT POLICY AND GUIDELINE CHANGES IN THE EU-5 DURING THE COVID-19 PANDEMIC ERA : AN INSIGHT INTO TRENDS AND DRIVERS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Ghosh S, Chatterjee M
	HTA255	RECOMMENDATIONS ON THE USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SYSTEMATIC LITERATURE REVIEWS SUBMITTED AS PART OF THE EVIDENCE PACKAGE IN HEALTH TECHNOLOGY ASSESSMENT **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Ferizovic N, Rtveladze K
	HTA259	OVERLAPS AND DIFFERENCES IN THE PICO CRITERIA BETWEEN THE DIFFERENT EU COUNTRIES **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Gallinger P, Bonduelle D, Mattern F, Plantör S, Schmalhofer C, Streicher S, Troubat A, van Engen A
	HTA270	USE OF PATIENT PREFERENCE STUDIES TO SUPPORT HTA SUBMISSIONS IN ONCOLOGY **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Rodriguez-Leboeuf AM, Genel T, Srivastava P, Lai L, Afroz N
METHODOLOGICAL & STATISTICAL RESEARCH	MSR124	DEVELOPMENT OF A MACHINE LEARNING PREDICTIVE MODEL FOR STROKE AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION RECEIVING ORAL ANTICOAGULANT TREATMENT **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Rebollo P, Wolk A, Luczko M, Tang JP
	MSR127	GENERALIZABILITY OF TRIAL-BASED ECONOMIC EVALUATIONS. METHODS TO ACCOUNT FOR COVARIATES AND IMPACT ON COST-EFFECTIVENESS AND VALUE OF INFORMATION **GERIATRICS**	Mantopoulos T, Dias S, Welton N
	MSR140	CASE STUDY COMPARING ANCHORED VS UNANCHORED APPROACHES TO DERIVING TIME-VARYING HAZARD RATIOS UNDER VIOLATION OF THE PROPORTIONAL HAZARDS ASSUMPTION **DRUGS**	Sandhu H, Nikolaidis G, Tasoulas A, Gaultney J
PATIENT-CENTERED RESEARCH	PCR253	ESTABLISHING CONTENT VALIDITY OF THREE NEW PATIENT REPORTED OUTCOME (PRO) MEASURES FOR USE IN HIV LONG-ACTING ORAL ANTIRETROVIRAL THERAPY (LA-OART) CLINICAL TRIALS **NO ADDITIONAL DISEASE & CONDITIONS/SPECIALIZED TREATMENT AREAS**	Bailey JR, Javidnia P, Fonseca E, Borsa A, Hawryluk E, Gubernick SI, de la Motte A, Karantzoulis S, Reaney M, Saretsky TL
	PCR282	DESPITE THE GROWING WEIGHT OF PATIENT VOICE IN MEDICAL RESEARCH, ONLY FEW MEDICAL JOURNALS ALLOW AND/OR REQUIRE PLAIN LANGUAGE SUMMARIES (PLS) **SENSORY SYSTEM DISORDERS (EAR, EYE, DENTAL, SKIN)**	Obis T, Avila M, Casamayor M
REAL-WORLD DATA & INFORMATION	RWD140	BENEFITS AND CHALLENGES OF DETERMINISTIC, PROBABILISTIC, AND PATIENT-MEDIATED APPROACHES TO LINKING PATIENTS' CLINICAL TRIAL DATA (CTD) AND THEIR REAL-WORLD DATA (RWD) **BIOLOGICS & BIOSIMILARS, GENETIC, REGENERATIVE & CURATIVE THERAPIES, MEDICAL DEVICES, PERSONALIZED & PRECISION MEDICINE**	Zabell T, Jeswani N, Hahn K, Coutcher J, Papsch R

Click here for details of posters available on the ISPOR Europe 2022 website

Live demonstrations at IQVIA booth X3-306

ADVANCED HTA SOLUTIONS

A clearer path to market access

Accelerate a successful launch with instant insights into payer decision-making across 40 countries

IQVIA CORE DIABETES MODEL

Robust, validated simulation of costs and outcomes in diabetes

Understand the clinical and economic impact of interventions in type 1 and type 2 diabetes

COA ACCELERATOR

A platform for optimizing your clinical outcome assessment strategies

Accelerate your assessment of clinical outcomes with powerful information and insights

XNET – HTA DASHBOARD

HTA outcome prediction using AI/ML

Leverage AI and Machine Learning models to anticipate HTA outcomes

ATLAS

Large-scale global research through a federated data network

Conduct observational health research remotely leveraging the OMOP common data model and ATLAS analytics software tool



To book a personal demonstration or to schedule a meeting with our experts at ISPOR Europe 2022, please email our team at:
rweinfo@iqvia.com



CONTACT US

iqvia.com

©2022. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. 10.2022.RWS